Therapeutic options for Acinetobacter baumannii infections
1Hospital Clinic, Department of Clinical Microbiology, Villarroel, 170; 08036 Barcelona, Spain. jvila@ub.edu
Expert Opinion on Pharmacotherapy
|March 4, 2008
Summary
Acinetobacter baumannii causes serious hospital infections and is resistant to many antibiotics, including colistin. Careful treatment is crucial due to high mortality rates associated with these infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Acinetobacter baumannii is a primary cause of hospital-acquired infections, particularly in intensive care units.
- This bacterium exhibits significant multidrug resistance, posing a major clinical challenge.
- Resistance to colistin, a last-resort antibiotic, is increasingly observed.
Purpose of the Study:
- To review the evolution of antimicrobial resistance in Acinetobacter baumannii.
- To analyze the molecular mechanisms underlying increasing antimicrobial resistance.
- To discuss current treatment strategies for Acinetobacter infections.
Main Methods:
- Literature review of antimicrobial resistance trends.
- Analysis of molecular epidemiology and resistance mechanisms.
- Synthesis of current clinical guidelines and treatment outcomes.
Main Results:
- Acinetobacter baumannii demonstrates widespread multidrug resistance globally.
- Molecular factors contribute significantly to the rise in antimicrobial resistance.
- Infections by A. baumannii are associated with substantial attributable mortality.
- Inappropriate treatment correlates with increased mortality in pneumonia and bacteremia.
Conclusions:
- Acinetobacter baumannii represents a critical threat in healthcare settings due to its resistance profile.
- Understanding resistance evolution and molecular basis is key to effective management.
- Judicious and appropriate antimicrobial selection is paramount to improve patient outcomes and reduce mortality.
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...